2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
2
Breast
2
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
339
Nivolumab
305
Ipilimumab
274
Cyclophosphamide
194
aldesleukin
148
Interleukin-2
110
fludarabine phosphate
106
trametinib
85
Temozolomide
83
Dacarbazine
81
fludarabine
80
dabrafenib
77
Radiotherapy
75
Biopsy
75
Vemurafenib
71
Imiquimod
53
Bevacizumab
51
sargramostim
50
Radiosurgery
49
Peripheral Blood Stem Cell Transplantation
49
Paclitaxel
49
Magnetic Resonance Spectroscopy
49
Aminolevulinic Acid
49
binimetinib
48
Carboplatin
48
Specimen Handling
47
Blood Specimen Collection
47
cemiplimab
46
Cisplatin
45
3-ingenyl angelate
45
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Isoflurane
×
Dermatologic
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled